This federal Project Grant award of $473,216 from the National Institute on Aging's Aging Research program (CFDA 93.866) supports a project by MCM6 Therapeutics, Inc. to identify small molecule therapeutics that can reduce aberrant lipid accumulation in Alzheimer's disease patients with the APOE4 genetic risk factor. The project will utilize a high-content screening pipeline developed by the company's Chief Science Advisor to model APOE4-driven lipid accumulation in human oligodendrocytes. The...
The U.S. National Institute on Aging (NIA) has awarded a $3,474,488 Cooperative Agreement under the Aging Research Grant Program (CFDA 93.866) to Emory University to develop a small-molecule antagonist of the EP2 receptor as a potential disease-modifying treatment for Alzheimer's disease (AD). The project aims to define the pharmacokinetic and pharmacodynamic (PK/PD) relationships of the lead EP2 antagonist candidates on AD pathology markers in two different mouse models of early-onset and...
This Project Grant award of $500,000 from the National Institute on Aging (CFDA 93.866 Aging Research) supports the development of a multi-target peptide drug called ALZ100 by Alzarrok Bio LLC for the treatment of Alzheimer's disease (AD). The project aims to demonstrate the in vivo efficacy of ALZ100 in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The key products and services to be delivered include: Infusing wild-type and AD transgenic mouse brains with varying...
This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) provides $1,012,534 to Eydis Bio, Inc. to develop orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's disease. The award aims to identify suitable TAK1 inhibitors with optimal central nervous system penetrance that can be advanced into in vivo testing in the PS19 mouse model. The project builds on Eydis Bio's...
The National Institute on Aging (NIA) awarded Neucyte Inc., a minority-owned small business, a $500,000 Project Grant under the Aging Research program (CFDA 93.866) to develop a nanoluciferase-based microphysiological systems platform for high-throughput screening of Alzheimer's disease (AD) and AD-related dementia (ADRD) therapeutics. The platform will utilize induced pluripotent stem cell-derived "mini-brain" assembloids to create scalable, reproducible 3D brain models that better...
This federal Project Grant award of $679,424, provided by the National Institute on Aging under the Aging Research program (CFDA 93.866), supports a comprehensive preclinical study to evaluate the efficacy of a novel nanoligomer therapeutic for reducing neuroinflammation and protecting cognitive function in animal models of brain aging and Alzheimer's disease. The primary grantee, Colorado State University, will conduct a series of experiments administering the NF-kB/NLRP3-targeted nanoligomer...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize these APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying lead candidates for further preclinical development and potential...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,998 to Encue Inc., a small disadvantaged business, to develop novel small molecule modulators of synaptic plasticity for the treatment of Alzheimer's disease (AD)-induced cognitive decline. The project aims to further develop the lead molecule JB2, which has shown potential to reverse cognitive deficits in a mouse model of Alzheimer's by restoring normal expression and function of...
The National Institute on Aging, under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $504,732 Project Grant to Aphios Corp on September 25, 2024 for the "Development of a Novel Alzheimer's Disease Therapeutic". The project aims to develop targeted nanoparticles containing an anti-CCR5 drug to address brain inflammation associated with Alzheimer's disease. In Phase I, the grant will fund the nanoencapsulation and characterization of the anti-CCR5 drug, as well as...
The National Institute on Aging (NIA) awarded a $682,000 Project Grant under the Aging Research Federal Grant Program (CFDA 93.866) to The Roskamp Institute, Inc., a non-profit biotechnology research organization in Sarasota, Florida. The grant, awarded from Sep 1, 2024 to May 31, 2026, will support research to investigate the influence of microglial cell depletion and repopulation on amyloid-related imaging abnormalities (ARIA) and vascular lesions in APOE4 carriers with Alzheimer's disease,...
The National Institutes of Health National Institute on Aging awarded Arviat Pharmaceuticals, Inc. a $1,350,180 Project Grant under the Aging Research program (CFDA 93.866) on September 30, 2021 to develop novel small-molecule inhibitors of the 12/15-lipoxygenase enzyme family. The goal is to reduce neuroinflammation and slow disease progression in Alzheimer's disease by inhibiting 12/15-LO activity. Under the award, Arviat will screen compounds from existing patent portfolios and develop second-generation oral 12/15-LO inhibitors with greater efficacy than first-generation drugs. The work includes synthesizing 100 compounds, conducting enzyme and cellular assays to prioritize compounds, testing leading candidates in neuroprotection and pharmacokinetic assays, and identifying at least three compounds for further evaluation. Successful completion could lead to a lead compound for clinical trials as a potential disease-modifying Alzheimer's treatment. Sub-awardee Acurex Biosciences Corp will provide support on unspecified tasks.